Invivo anti-Human GM-CSF Recombinant mAb

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as CSF2, is a multifunctional glycoprotein cytokine that serves as a critical regulator of hematopoiesis and immune responses by binding to a specific heterodimeric receptor complex composed of an alpha chain (CD116) and a shared beta chain (CD131) on target cells. Primarily produced by activated macrophages, T cells, mast cells, endothelial cells, and fibroblasts in response to inflammatory stimuli, GM-CSF stimulates the proliferation, differentiation, survival, and functional activation of myeloid progenitor cells, driving their development into mature granulocytes (such as neutrophils, eosinophils, and basophils) and monocytes/macrophages while simultaneously enhancing the antimicrobial and antigen-presenting capabilities of these mature cells through mechanisms like increased phagocytosis, oxidative burst, and upregulation of MHC class II molecules. Beyond its physiological role in boosting host defense against infections and maintaining tissue homeostasis, GM-CSF plays a significant pathological role in chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, where its overproduction contributes to sustained inflammation and tissue damage, making it a prominent therapeutic target for monoclonal antibodies aimed at blocking its signaling pathway, while recombinant forms of the protein (e.g., sargramostim) are clinically utilized to accelerate myeloid recovery following chemotherapy or bone marrow transplantation.